Clinical trial · Observational
Multicenter Retrospective Study on Patients Treated with Stereotactic Radiosurgery/Radiotherapy for Single Brain Lesions: Evaluation of Treatment Efficacy and Safety, Also Through Radiomic Analysis Methods.
STEREOMIC: Studio Retrospettivo Multicentrico Su Pazienti Trattati Con Radiochirurgia/Radioterapia STEREotassica Per Lesioni Encefaliche Singole. Valutazione Di Efficacy E Safety Del Trattamento Anche Mediante Metodiche Di Analisi RadiOMICa
NCT06869460CI-TRIAL-00087014STEREOMICactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study design concerns all patients diagnosed witha singular brain metastasis who underwent stereotactic radiosurgery/radiotherapy between January 2010 and December 2022
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | — | UNRESOLVED | — |
| Radiotherapy Side Effect | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Stereotactic Body Radiotherapy/Radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with a singular brain metastases
- description
- The study design concerns all patients diagnosed with brain metastases who underwent stereotactic radiosurgery/radiotherapy between January 2010 and December 2022
- interventionNames
- Radiation: Stereotactic Body Radiotherapy/Radiosurgery
Primary outcomes (2)
- measure
- Toxicity profile
- timeFrame
- due to the retrospective nature of the study, we did not have specific time points.We will evaluate the possible onset of toxicity events from the last day of treatment up to 18 months from the treatment
- description
- "The toxicity profile of the treatment will be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute."
- measure
- Local control
- timeFrame
- We will evaluate Lc at one, two, and five years from the treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Treatment with SRS/SRT techniques for a single secondary brain lesion * Availability of pre-RT brain MRI with contrast (1mm slice thickness) * Availability of CT simulation imaging for treatment * Availability of relevant clinical data in the medical record for the study's objectives * Follow-up of at least 6 months after the completion of SRS or SRT * Follow-up evaluation through brain MRI Exclusion Criteria: * Age under 18 years * Lack of clinical/radiological data for the patient * Unavailability of the required imaging * Previous whole-brain radiotherapy treatment
References
Publications (0)
Data not yet available
No reference posted for this study.